BMJ Study: GLP-1 Drugs Such as Ozempic and Mounjaro Linked to Higher Risk of Hair Loss in Adults with Type 2 Diabetes
A new study published in The BMJ has found that adults with type 2 diabetes who use glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), may face a higher risk of developing non-scarring hair loss (alopecia) compared with patients taking other commonly prescribed diabetes medicines.








About Authors

Harsh Bhardwaj1*, Sakshi Jain2, Raaz K Maheshwari3


